Entera Bio Company Insiders
| ENTX Stock | USD 2.33 0.05 2.10% |
Entera Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Entera Bio suggests that vertually all insiders are extremely bullish. Entera Bio employs about 17 people. The company is managed by 5 executives with a total tenure of roughly 40 years, averaging almost 8.0 years of service per executive, having 3.4 employees per reported executive.
Entera Bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-01-12 | Haya Taitel | Acquired 9500 @ 0.99 | View | ||
| 2024-01-10 | Haya Taitel | Acquired 7615 @ 0.77 | View | ||
| 2023-12-22 | Miranda Jayne Toledano | Acquired 23952 @ 0.71 | View | ||
| 2023-08-21 | Sean Ellis | Acquired 40000 @ 0.6 | View | ||
| 2023-04-04 | Miranda Jayne Toledano | Acquired 30000 @ 1.01 | View | ||
| 2022-11-11 | Sean Ellis | Acquired 30000 @ 0.53 | View | ||
| 2022-07-21 | Sean Ellis | Acquired 14900 @ 1.64 | View |
Monitoring Entera Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Entera |
Entera Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Entera Bio's future performance. Based on our forecasts, it is anticipated that Entera will maintain a workforce of slightly above 20 employees by March 2025.Entera Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.7061) % which means that it has lost $0.7061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4467) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.71 in 2025. Return On Capital Employed is likely to drop to -1.01 in 2025. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2025, whereas Other Current Assets are likely to drop slightly above 209 K in 2025.Common Stock Shares Outstanding is likely to drop to about 19.3 M in 2025. Net Loss is likely to drop to about (12.4 M) in 2025
Entera Bio Workforce Comparison
Entera Bio is rated # 2 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 64.0. Entera Bio totals roughly 17.0 in number of employees claiming about 27% of equities under Health Care industry.
Entera Bio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Entera Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 0.5714 | 4 | 7 | 320,302 | 349,900 |
| 2022-03-01 | 1.4211 | 27 | 19 | 1,137,695 | 3,716,804 |
Entera Bio Notable Stakeholders
An Entera Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Entera Bio often face trade-offs trying to please all of them. Entera Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Entera Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hillel MBA | Chief Officer | Profile | |
| Miranda MBA | CEO Director | Profile | |
| II MD | Chief Officer | Profile | |
| Gregory Burshtein | Chief Development | Profile | |
| Dana CPA | Chief Officer | Profile |
About Entera Bio Management Performance
The success or failure of an entity such as Entera Bio often depends on how effective the management is. Entera Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Entera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Entera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.96) | (1.01) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (0.98) | (1.03) |
Please note, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Check Entera Bio's Beneish M Score to see the likelihood of Entera Bio's management manipulating its earnings.
Entera Bio Workforce Analysis
Traditionally, organizations such as Entera Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Entera Bio within its industry.Entera Bio Manpower Efficiency
Return on Entera Bio Manpower
| Revenue Per Employee | 824 | |
| Revenue Per Executive | 2.8K | |
| Net Loss Per Employee | 522.9K | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 598K | |
| Working Capital Per Executive | 2M |
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.